• Product nameAnti-CD26 antibody [202-36]
    See all CD26 primary antibodies
  • Description
    Mouse monoclonal [202-36] to CD26
  • Tested applicationsSuitable for: IHC-Fr, WB, ICC/IF, Flow Cytmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: RatDoes not react with: Sheep, Pig
  • Immunogen

    Human T cell clone.

  • Positive control
    • HEP-G2 cells. Lymph node or tonsil.


Associated products


Our Abpromise guarantee covers the use of ab3154 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt
  • Application notesFlow Cyt: Use at an assay dependent concentration.
    ICC/IF: Use at an assay dependent dilution (PMID 17959672).
    WB: Use at a concentration of 5 µg/ml. Detects a band of approximately 130 kDa (predicted molecular weight: 88 kDa).

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionCell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC. Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Its interaction with ADA also regulates lymphocyte-epithelial cell adhesion. In association with FAP is involved in the pericellular proteolysis of the extracellular matrix (ECM), the migration and invasion of endothelial cells into the ECM. May be involved in the promotion of lymphatic endothelial cells adhesion, migration and tube formation. When overexpressed, enhanced cell proliferation, a process inhibited by GPC3. Acts also as a serine exopeptidase with a dipeptidyl peptidase activity that regulates various physiological processes by cleaving peptides in the circulation, including many chemokines, mitogenic growth factors, neuropeptides and peptide hormones. Removes N-terminal dipeptides sequentially from polypeptides having unsubstituted N-termini provided that the penultimate residue is proline.
    • Tissue specificityExpressed specifically in lymphatic vessels but not in blood vessels in the skin, small intestine, esophagus, ovary, breast and prostate glands. Not detected in lymphatic vessels in the lung, kidney, uterus, liver and stomach (at protein level). Expressed in the poorly differentiated crypt cells of the small intestine as well as in the mature villous cells. Expressed at very low levels in the colon.
    • Sequence similaritiesBelongs to the peptidase S9B family. DPPIV subfamily.
    • DomainThe extracellular cysteine-rich region is necessary for association with collagen, dimer formation and optimal dipeptidyl peptidase activity.
    • Post-translational
      The soluble form (Dipeptidyl peptidase 4 soluble form also named SDPP) derives from the membrane form (Dipeptidyl peptidase 4 membrane form also named MDPP) by proteolytic processing.
      N- and O-Glycosylated.
      Phosphorylated. Mannose 6-phosphate residues in the carbohydrate moiety are necessary for interaction with IGF2R in activated T-cells. Mannose 6-phosphorylation is induced during T-cell activation.
    • Cellular localizationCell membrane. Apical cell membrane. Cell projection > invadopodium membrane. Cell projection > lamellipodium membrane. Cell junction. Membrane raft. Translocated to the apical membrane through the concerted action of N- and O-Glycans and its association with lipid microdomains containing cholesterol and sphingolipids. Redistributed to membrane rafts in T-cell in a interleukin-12-dependent activation. Its interaction with CAV1 is necessary for its translocation to membrane rafts. Colocalized with PTPRC in membrane rafts. Colocalized with FAP in invadopodia and lamellipodia of migratory activated endothelial cells in collagenous matrix. Colocalized with FAP on endothelial cells of capillary-like microvessels but not large vessels within invasive breast ductal carcinoma. Colocalized with ADA at the cell junction in lymphocyte-epithelial cell adhesion. Colocalized with IGF2R in internalized cytoplasmic vesicles adjacent to the cell surface and Secreted. Detected in the serum and the seminal fluid.
    • Information by UniProt
    • Database links
    • Alternative names
      • CD26 antigen antibody
      • ADA-binding protein antibody
      • ADABP antibody
      • ADCP 2 antibody
      • ADCP-2 antibody
      • ADCP2 antibody
      • Adenosine deaminase complexing protein 2 antibody
      • CD 26 antibody
      • CD26 antibody
      • CD26 antigen 3 antibody
      • Dipeptidyl peptidase 4 antibody
      • Dipeptidyl peptidase 4 soluble form antibody
      • Dipeptidyl peptidase IV antibody
      • Dipeptidyl peptidase IV membrane form antibody
      • Dipeptidyl peptidase IV soluble form antibody
      • Dipeptidyl peptidase, intestinal antibody
      • Dipeptidylpeptidase 4 antibody
      • Dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2) antibody
      • Dipeptidylpeptidase IV antibody
      • DPP 4 antibody
      • DPP IV antibody
      • DPP IV estoenzyme antibody
      • DPP4 antibody
      • DPP4_HUMAN antibody
      • DPPIV antibody
      • Intestinal dipeptidyl peptidase antibody
      • T cell activation antigen CD26 antibody
      • T-cell activation antigen CD26 antibody
      • TP 103 antibody
      • TP103 antibody
      see all

    Anti-CD26 antibody [202-36] images

    • All lanes : Anti-CD26 antibody [202-36] (ab3154) at 5 µg/ml

      Lane 1 : U-87 MG (Human glioblastoma astrocytoma) Whole Cell Lysate
      Lane 2 : Ramos (Human Burkitt's lymphoma cell line) Whole Cell Lysate

      Lysates/proteins at 10 µg per lane.

      Goat polyclonal to Mouse IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution

      Predicted band size : 88 kDa

    References for Anti-CD26 antibody [202-36] (ab3154)

    This product has been referenced in:
    • Aliagas E  et al. Ecto-nucleotidases distribution in human cyclic and postmenopausic endometrium. Purinergic Signal 9:227-37 (2013). IHC-Fr ; Human . Read more (PubMed: 23225236) »
    • Mee CJ  et al. Effect of cell polarization on hepatitis C virus entry. J Virol 82:461-70 (2008). ICC/IF ; Human . Read more (PubMed: 17959672) »

    See all 2 Publications for this product

    Product Wall

    Thank you for your enquiry and your interest in our products. We regret to inform you that this antibody has not been tested for functional or neutralizing studies.